

Accepted Manuscript

Title: An Old Friend is Trouble for Double-Expressor and Double-Hit Lymphoma

Author: Michael Scordo


PII: S1083-8791(18)30027-2
DOI: <https://doi.org/10.1016/j.bbmt.2018.01.012>
Reference: YBBMT 54999

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 8-1-2018
Accepted date: 9-1-2018

Please cite this article as: Michael Scordo, An Old Friend is Trouble for Double-Expressor and Double-Hit Lymphoma, *Biology of Blood and Marrow Transplantation* (2018), <https://doi.org/10.1016/j.bbmt.2018.01.012>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Title:** An Old Friend is Trouble for Double-Expressor and Double-Hit Lymphoma

2

3 **Author:** Michael Scordo, MD^{1,2}

4 Michael Scordo, MD

5 Assistant Attending

6 Adult Bone Marrow Transplant Service

7 Department of Medicine

8 Memorial Sloan Kettering Cancer Center

9 1275 York Avenue

10 New York, NY 10065

11 E-mail: scordom@mskcc.org

12 Phone: 212-639-6052

13 Fax: 212-717-3394

14

15 **Affiliations:**

16 ¹Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan
17 Kettering Cancer Center

18 ²Department of Medicine, Weill Cornell Medical College

19

20 **Keywords:** Double-expressor lymphoma; Double-hit lymphoma; Allogeneic

21 Hematopoietic Cell Transplantation

22

23 **Conflicts of Interest:** There are no other relevant conflicts of interests in relation to the
24 work described.

25

26 **Commentary:** It is now well established that patients with aggressive subtypes of diffuse

27 large B-cell lymphoma (DLBCL), namely double-expressor lymphoma (DEL) and double-

28 hit lymphoma (DHL), have unfavorable outcomes after standard chemo-immunotherapy

29 induction.¹ Even patients with DEL and DHL who achieve chemosensitive remission

30 after initial relapse fare worse after consolidative high-dose therapy and autologous stem

31 cell transplantation than their counterparts without these distinct disease subtypes.^{2,3}

32 Many in the field have justifiably called for innovative approaches to tackling these

33 entities as an area of unmet need.

34

35 In this issue of BBMT, Herrera et al. remind us that in an era of ever-expanding use of

36 novel immunotherapies and cellular therapies, sometimes old, familiar friends should not

Download English Version:

<https://daneshyari.com/en/article/8429988>

Download Persian Version:

<https://daneshyari.com/article/8429988>

[Daneshyari.com](https://daneshyari.com)